Crafting Democratic Futures: Understanding Political Conditions and Racialized Attitudes Toward Black Reparations

As a growing number of states and municipalities consider reparative policies for Black Americans, it is important to understand what shapes support for and opposition to these policies. We explore the role that awareness of racial inequality plays in shaping attitudes. Drawing on data from a large, representative survey in Detroit and one national survey, we find that awareness of racial inequality plays a powerful role in the likelihood of supporting reparative policies. Yet, in follow-up surveys, we find that exposing respondents to information on the rationale for and importance of reparations does not shift public support. These findings suggest that it is the awareness of racial inequality that is cultivated over time that appears to be the dominant force in building support for reparations. These findings are particularly important during a time when many school districts are severely restricting access to information about the history of Black Americans

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

A STUDY OF THE IDEA OF REVELATION, WITH SPECIAL REFERENCE TO THE THOUGHT OF PAUL TILLICH AND KARL BARTH.

Abstract not availabl

Ping-through-the-hull 3.5 kHz echo-sounding systems on the research vessels CHAIN, ATLANTIS II, and KNORR

This report documents the 3.5. kHz sounding systems currently in use on Woods Hole research vessels. To help others to install similar facilities, we discuss the history, installation technique, performance and calibrations of our various systems.Prepared for the 0ffice of Naval Research under Contract N00014-74-C-0262; NR 083-004

Work and wages, in continuation of Lord Brassey's 'Work and wages' and 'Foreign work and English wages' ...

Mode of access: Internet

Supplemental Material - A Qualitative Model of Weight Cycling

Supplemental Material for A Qualitative Model of Weight Cycling by Lynsey Romo, Sydney Earl, Katelin Mueller, and Mary Obiol in Qualitative Health Research</p